CoChat

Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Despite recent progress in the treatment, the outcome of adult acute T-cell lymphoblastic leukemia (T-ALL) is poor. Development of novel approach to combat this disease is urgently required. Vorinostat, a pan-histone deacetylase (HDAC) inhibitor, exerts promising anticancer activity in a variety of solid and hematologic malignancies. However, the efficacy of vorinostat monotherapy is unsatisfactory. Here, we show that quinacrine (QC), an anti-malaria drug with potent autophagy inhibitory activity, could synergistically enhance vorinostat-induced cell death at a non-toxic concentration. Compared to the single treatment, QC plus vorinostat significantly induced apoptosis, disrupted the mitochondrial transmembrane potential, and decreased Mcl-1 and Bcl-2/Bax ratio. Interestingly, the application of QC plus vorinostat resulted in mitophagy blockade, as reflected by the increase in the K63-linked ubiquitination of mitochondria protein and the formation of mitochondrial aggresomes. QC plus vorinostat markedly increased the reactive oxygen species (ROS) level in cells. Moreover, the ROS scavenger N-acetylcysteine (NAC) abrogated QC plus vorinostat-induced ROS, decreased the ubiquitination of mitochondria proteins, and cell death. Finally, using a xenograft mouse model, we demonstrated that QC plus vorinostat significantly reduced cell proliferation and induced cell death in vivo. Taken together, our results showed that the combination of QC with vorinostat may represent a novel regimen for the treatment of T-cell acute lymphoblastic leukemia, which deserves clinical evaluation in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-018-0679-6

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 QC enhances vorinostat-inhibited cell viability in T-ALL cells. a, b Jurkat and Molt-4 cells were treated with the indicated dose of vorinostat or QC for an indicated time or the combination of both, and then the cell viability were monitored by trypan blue staining. c, d Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) and Molt-4 cells were treated with vorinostat (1 μM) and/or QC (2.5 μM) for an indicated time. Cell viability was monitored by trypan blue staining (c). The morphology of the cells was observed by Wright staining (d). e CIs were analyzed with the program CompuSyn in Jurkat and Molt-4 cells. CI value <1 indicates that the two drugs have synergic effects. f PBMCs from T-ALL patients were treated with vorinostat (1 μM) and QC (5 μM) for 24 and 48 h, and the cell viability was monitored by trypan blue staining. g PBMCs were treated with vorinostat (1 μM) and QC (5 μM) for 48 h, and the cell viability was monitored by trypan blue staining. *p < 0.05, **p < 0.01, and ***p < 0.001. All experiments were performed at least three times with the same results
Fig. 1 QC enhances vorinostat-inhibited cell viability in T-ALL cells. a, b Jurkat and Molt-4 cells were treated with the indicated dose of vorinostat or QC for an indicated time or the combination of both, and then the cell viability were monitored by trypan blue staining. c, d Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) and Molt-4 cells were treated with vorinostat (1 μM) and/or QC (2.5 μM) for an indicated time. Cell viability was monitored by trypan blue staining (c). The morphology of the cells was observed by Wright staining (d). e CIs were analyzed with the program CompuSyn in Jurkat and Molt-4 cells. CI value <1 indicates that the two drugs have synergic effects. f PBMCs from T-ALL patients were treated with vorinostat (1 μM) and QC (5 μM) for 24 and 48 h, and the cell viability was monitored by trypan blue staining. g PBMCs were treated with vorinostat (1 μM) and QC (5 μM) for 48 h, and the cell viability was monitored by trypan blue staining. *p < 0.05, **p < 0.01, and ***p < 0.001. All experiments were performed at least three times with the same resultsCC BY · PubMed Central
Fig. 2 Effects of vorinostat and QC on the apoptosis of Jurkat and Molt-4 cells. Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 48 h and Molt-4 cells were treated with vorinostat (1 μM) and/or QC (2.5 μM) for 24 h. a, b Cell cycle distribution of Jurkat and Molt-4 cells was analyzed by flow cytometry. c, d Apoptosis rate of Jurkat and Molt-4 cells was established by flow cytometry analysis of Annexin-V-PI dual staining. e The indicated proteins were examined by western blots. *p < 0.05, **p < 0.01. All experiments were performed at least three times with the same results
Fig. 2 Effects of vorinostat and QC on the apoptosis of Jurkat and Molt-4 cells. Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 48 h and Molt-4 cells were treated with vorinostat (1 μM) and/or QC (2.5 μM) for 24 h. a, b Cell cycle distribution of Jurkat and Molt-4 cells was analyzed by flow cytometry. c, d Apoptosis rate of Jurkat and Molt-4 cells was established by flow cytometry analysis of Annexin-V-PI dual staining. e The indicated proteins were examined by western blots. *p < 0.05, **p < 0.01. All experiments were performed at least three times with the same resultsCC BY · PubMed Central
Fig. 3 The synergic effects of vorinostat plus QC treatment on the change of mitochondrial transmembrane potential (ΔΨm). a–c Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 48 h and Molt-4 cells were treated with vorinostat (1 μM) and/or QC (2.5 μM) for 24 h. a ΔΨm was quantified by flow cytometry analysis of JC-1 staining. b Statistical analysis of a; c the indicated proteins were detected by western blotting analysis; d Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 30 h. DHE staining was used to analyze the level of ROS in cells; e Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) in the presence or absence of NAC (10 mM) for 48 h, and the cell viability was monitored by trypan blue staining. **p < 0.01, and ***p < 0.001. All experiments were performed at least three times with the same results
Fig. 3 The synergic effects of vorinostat plus QC treatment on the change of mitochondrial transmembrane potential (ΔΨm). a–c Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 48 h and Molt-4 cells were treated with vorinostat (1 μM) and/or QC (2.5 μM) for 24 h. a ΔΨm was quantified by flow cytometry analysis of JC-1 staining. b Statistical analysis of a; c the indicated proteins were detected by western blotting analysis; d Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 30 h. DHE staining was used to analyze the level of ROS in cells; e Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) in the presence or absence of NAC (10 mM) for 48 h, and the cell viability was monitored by trypan blue staining. **p < 0.01, and ***p < 0.001. All experiments were performed at least three times with the same resultsCC BY · PubMed Central
Fig. 4 The combination of vorinostat and QC blocks mitophagy and accumulation of mito-aggresomes. (a, b, d) Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 36 h. a The indicated proteins in the cytoplasm and mitochondria were examined by western blot. b TEM of cells; the red arrows indicate the damaged mitochondria that are wrapping in double-membrane structures. c Jurkat cells treated with vorinostat (1 μM) and/or QC (5 μM) in the presence or absence of NAC (10 mM) for 36 h, and then the indicated proteins were examined by western blot. d The expression levels of K63-linked and K48-linked ubiquitinated proteins in the mitochondria were examined by western blot. All experiments were performed at least three times with the same results
Fig. 4 The combination of vorinostat and QC blocks mitophagy and accumulation of mito-aggresomes. (a, b, d) Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) for 36 h. a The indicated proteins in the cytoplasm and mitochondria were examined by western blot. b TEM of cells; the red arrows indicate the damaged mitochondria that are wrapping in double-membrane structures. c Jurkat cells treated with vorinostat (1 μM) and/or QC (5 μM) in the presence or absence of NAC (10 mM) for 36 h, and then the indicated proteins were examined by western blot. d The expression levels of K63-linked and K48-linked ubiquitinated proteins in the mitochondria were examined by western blot. All experiments were performed at least three times with the same resultsCC BY · PubMed Central
Fig. 5 Vorinostat in combination with QC inhibits T-ALL cell growth in vivo. Mice were treated as described in material and method. a, b Tumor volume (a) and mice weight (b) were shown. c Mice tumor sections from each groups were subjected to immunostaining using TUNEL and anti-Ki-67 Abs. *p < 0.05
Fig. 5 Vorinostat in combination with QC inhibits T-ALL cell growth in vivo. Mice were treated as described in material and method. a, b Tumor volume (a) and mice weight (b) were shown. c Mice tumor sections from each groups were subjected to immunostaining using TUNEL and anti-Ki-67 Abs. *p < 0.05CC BY · PubMed Central
Fig. 6 Schematic representation of the mechanisms underlying apoptosis induced by vorinostat in combination with QC. The treatment with vorinostat in combination with QC induced an increase in the level of intracellular ROS, further promoting mitochondrial dysfunction and the accumulation of K63-linked ubiquitination of the mitochondria, which indicates mitophagy. QC blocked autophagy flow through lysosomal dysfunction, resulting in the accumulation of mito-aggresomes and eventually inducing T-ALL cell death
Fig. 6 Schematic representation of the mechanisms underlying apoptosis induced by vorinostat in combination with QC. The treatment with vorinostat in combination with QC induced an increase in the level of intracellular ROS, further promoting mitochondrial dysfunction and the accumulation of K63-linked ubiquitination of the mitochondria, which indicates mitophagy. QC blocked autophagy flow through lysosomal dysfunction, resulting in the accumulation of mito-aggresomes and eventually inducing T-ALL cell deathCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 38

Metadata

Authors
Jing, B., Jin, J., Xiang, R., Liu, M., Yang, L., Tong, Y., Xiao, X., Lei, H., Liu, W., Xu, H., Deng, J., Zhou, L., & Wu, Y.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
  • Deng, Jiong
  • Zhou, Li
  • Wu, Yingli
Venue
Cell Death & Disease
Published
2018-05-22
Volume
9
Issue
6
Pages
589-589
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2803683563
Cited by
38
References
39
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 5
FWCI
4.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (81570118, 973 Program, 81570112, 2015CB910403, 2017YFA0505200)
  • Shanghai Municipal Education Commission
  • National Key Research and Development Program of China (2017YFA0505200, 2015CB910403)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Keywords
vorinostat, quinacrine, T-cell acute lymphoblastic leukemia, histone deacetylase inhibitors, drug synergy, reactive oxygen species, mitochondrial ubiquitination, apoptosis, Mcl-1, Bcl-2/Bax ratio, N-acetylcysteine, autophagy inhibition, xenograft mouse model
MeSH terms
Vorinostat, Animals, Cell Survival, Drug Synergism, Humans, Mitochondria, Models, Biological, Quinacrine, Mice, SCID, Mice, Inbred NOD, Apoptosis, Reactive Oxygen Species, Cell Line, Tumor, Cell Proliferation, Membrane Potential, Mitochondrial, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Mitophagy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition. https://app.cochat.ai/papers/10.1038/s41419-018-0679-6
The paper
Jing, B., Jin, J., Xiang, R., Liu, M., Yang, L., Tong, Y., Xiao, X., Lei, H., Liu, W., Xu, H., Deng, J., Zhou, L., & Wu, Y. (2018). Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition. Cell Death & Disease. https://doi.org/10.1038/s41419-018-0679-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.